RPRosalyn Parker

Rosalyn Parker

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Rosalyn Parker has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Tonsillectomy Complications in Adults: A Retrospective Observational Cohort Study of National Health Service Patients in England Using Hospital Episode Statistics

    by Steven Powell, Kim Keltie, Ed O'TOole, Rachel A. O'LEary, Hayley Richardson, Paola Cognigni, Rosalyn Parker, James O'HAra, Benjamin Talks, Adam Donne, et al.

    Objectives: To characterise adult tonsillectomy procedures conducted in the NHS from routine administrative data in England and investigate trends in their associated complications over time. Design: Retrospective observational cohort study using routine data from Hospital Episode Statistics (HES). Setting: Acute NHS trusts in England are conducting adult tonsillectomy. Participants: Adults (> 16 years old) undergoing tonsillectomy procedure with a primary diagnosis of any non‐malignant indication, and with no current or historic cancer, or benign neoplasm. Main Outcome Measures: Number of procedures, in‐hospital complications, readmissions within 28 days and trends over time. Results: A total of 198 130 adult patients had a tonsillectomy between 1 April 2008 and 31st March 2023 in NHS trusts in England. The total number of procedures is falling over time. It is more commonly undertaken in women (68.3%), with 79.3% performed for tonsillitis. The majority (59.6%) are discharged on the same day, with 37.5% staying 1 night in hospital. 1.5% of patients had an in‐hospital complication, with a total of 1967 patients having a haemorrhage or surgical arrest of post‐operative bleeding from the tonsillar bed or adenoid; occurring more frequently in men (1.7% versus 0.7%, p < 0.001). A total of 33 934 patients were readmitted as an emergency within 28 days of surgery, almost doubling between 2008/09 and 2022/23. Readmission with bleeding within 28 days has also increased from 8.8% in 2008/09 to 15.6% in 2022/23. The return to theatre rate during readmissions has been relatively stable over the study time period with a higher proportion of admissions being managed without a further operative procedure. Conclusions: Tonsillectomy is a very common operation in the NHS in England. It currently has a readmission rate of 1 in 5 adults and this information is important for informed consent and local resource planning.

  • Surgery for benign prostate enlargement in England: 10‐year retrospective study of 155 874 patients

    by Toby Page, Edward O'TOole, Kim Keltie, Yehia Abdelmotagly, Hayley Richardson, Rosalyn Parker, Andrew J. Sims

    Objectives: To analyse the trend in surgical interventions of benign prostate enlargement (BPE) in the UK National Health Service (NHS) in England (prostatic urethral lift, transurethral water vapour therapy, prostate artery embolisation, photoselective vaporisation of the prostate, transurethral incision of the prostate, holmium laser enucleation of the prostate, transurethral vaporisation of the prostate, transurethral resection of the prostate [TURP], and open surgery) and report prevalence of peri‐procedural complications and subsequent risk of re‐intervention. Patients and Methods: A retrospective observational study using Hospital Episode Statistics to identify patients with BPE that received their first surgical treatment in any NHS hospital in England between April 2012 and November 2022. Patients were followed longitudinally until the end of the study or date of death. In‐hospital (complications, length of stay), and longer‐term outcomes (re‐admission, re‐treatment, death) were reported. A multivariable logistic regression model was built to analyse the relationship between associated odds of in‐hospital complication and surgical modality. Kaplan–Meier analysis (stratified by age) and multivariable Cox regression analysis was performed to investigate the relationship between associated risk of re‐intervention between treatments. Results: A total of 155 874 patients underwent their first surgical intervention to treat BPE. Less invasive treatments were associated with significantly decreased odds of in‐hospital complication (compared to TURP). The effect of comorbidities and catheter on admission varied between treatments. Re‐intervention rate within 5 years for interventions where there was sufficient follow‐up varied from 3.1% (2.8–3.4%) to 19.6% (16.1–22.9%), less invasive treatments were associated with a significantly higher risk of re‐intervention compared to TURP. Conclusion: There is an increased uptake in minimally invasive treatments that require a shorter hospital stay and are associated with lower odds of treatment‐related complications. However, the long‐term effectiveness of these treatments varied, which should be taken into consideration by patients, clinicians and commissioners.


  • Open Access

    Knowledge and Practice in Cochlear Re-Implantation in the UK: A Survey for Audiologists

    by Muhammed Ayas, Rosalyn Parker, David Muir, Jameel Muzaffar

    Background: Cochlear implantation (CI) has proven to be a highly effective method for rehabilitating individuals with severe to profound hearing loss. However, challenges persist, particularly in cases where CI failure necessitates re-implantation. This study aims to address the gap in understanding the knowledge and practices of audiologists in the UK regarding cochlear re-implantation through a comprehensive questionnaire survey. Methods: A bespoke questionnaire was distributed to audiologists working with CI across the UK. The survey, which included multiple-choice items, open-text responses, and visual analogue scales, was made accessible via an online link shared through professional bodies, email groups, and social media platforms. Results: The survey received 27 responses, predominantly from female audiologists (71.4%), with significant representation from London (28.6%) and the East of England (21.4%). A majority of respondents had over 16 years of CI experience (35.7%) and held a master’s degree (60.7%). Key reasons for CI re-implantation included electrode failure (82.1%) and hermetic seal failure (60.7%). While respondents showed strong confidence in counselling (88.8%) and managing re-implanted devices (84.6%), there was a noted variation in opinions regarding the need for additional training in intraoperative measures. Conclusion: This survey highlights the current practices and training needs of UK audiologists in CI re-implantation. This underscores the importance of targeted training to fill knowledge gaps and improve clinical care during CI re-implantation, ultimately enhancing outcomes for both audiologists and CI recipients.

  • Early activation of cochlear implants: a systematic review and narrative synthesis

    by Rosalyn Parker, Jameel Muzaffar, Muhammed Ayas AuD, William Brassington

    Device activation typically occurs four weeks post cochlear implant surgery. Emerging evidence suggests earlier activation is feasible and beneficial, giving patients quicker access to sound and rehabilitation. Assess current literature for effects of early cochlear implant activation. Electronic searches of Medline/PubMed, AMED, EMBASE, CINAHL and the Cochrane Library following PRISMA guidelines. Studies investigating any aspect of early activation were included for review. From 15 studies, 625 patients received early activation, compared with 243 patients in the control groups. Early activation was considered as within 7 days post-operatively with 12 studies reporting within 1 day post-operatively, compared with standard activation of 9-46 days post-operatively in the control group. Some studies indicated earlier low levels of impedance in the early activation group. Magnet strength adjustment or off-ear processor wear was often recommended within the early activation cohort. Complication rates were low in both groups. Early activation improved patient satisfaction and anxiety levels without detriment to speech recognition or rehabilitation. Early cochlear implant activation is feasible and allows patients with no contraindications, earlier access to auditory perception and rehabilitation and reduces anxiety linked to delay in activation. Further evidence is required to monitor long-term effects of early activation.


  • Open Access

    Precision medicine in laryngeal cancer: protocol of the laryngeal cancer cohort (LARCH)

    by David Winston Hamilton, James O’hAra, Amarkumar Rajgor, Gerald Selby, Mhairi Anderson, Kim Keltie, Rosalyn Parker, Dawn Teare, Joanne Patterson, Terry M Jones, et al.

    Introduction Laryngeal cancer disproportionately affects socioeconomically disadvantaged patients. Treatment can render a patient nil by mouth or in need of a permanent tracheostomy. In the past 30 years, survival has remained at best static and at worst it has declined. Currently, there is no method of prognosticating how a patient will respond to treatment. The LARyngeal Cancer coHort (LARCH) aims to establish how survival and quality-of-life outcomes compare between surgery and (chemo)radiotherapy in early and advanced laryngeal cancer and how the presenting features of laryngeal cancer influence oncological, functional and quality-of-life outcome. Methods and analysis This study is the first enhanced laryngeal cancer disease cohort. In the initial phase, we aim to deliver a prospective cohort study of 150 patients in 8 centres over a 3-year period. Patient, tumour, quality-of-life and laryngeal functional data will be collected from patients with squamous cell carcinoma of the larynx at baseline, 6, 12 and 24 months. Multiple logistic regression analyses will be used to quantify locoregional control and identify factors associated with control overall and by treatment modality and identify factors associated with quality of life overall and by treatment modality. Ethics and dissemination Most interventions take place as part of routine care, with LARCH providing a mechanism for recording this data centrally. When successfully recruiting in the North of England, we plan to roll out LARCH nationwide; in the future, LARCH can be used as a trial platform in the disease. The results will be submitted for publication in high-impact international peer-reviewed journals and presented to scientific meetings. Access to the anonymised LARCH dataset by other researchers will be publicised and promoted. Trial registration number ISRCTN27819867.